Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1974 Mar;53(3):868–874. doi: 10.1172/JCI107627

Isolation of a Novel Glycoprotein from the Urine of a Patient with Chronic Myelocytic Leukemia

Daniel Rudman 1,2, Rajender K Chawla 1,2, Alejandro E Del Rio 1,2, Bettye Hollins 1,2
PMCID: PMC333069  PMID: 4204683

Abstract

Patient B. J. with chronic myelocytic leukemia excreted 0.5-1.1 g protein per day in the urine. Gel filtration on Sephadex G-75 showed about one-third of this protein to be in molecular weight range 20,000-40,000 (fraction BJC). BJC, prepared from 9 liters of urine by gel filtration, was chromatographed on carboxymethylcellulose. Two proteins were eluted from the resin in pure form (as shown by zone and immunoelectrophoresis) in yields representing 8 and 3 mg/liter of urine: BJC1 and BJC2. Their amino acid compositions were identical. BJC1 contained 61% carbohydrate (33% hexose, 11% sialic acid, 13% glucosamine, 5% galactosamine). BJC2 contained one-fourth to one-half as much of each carbohydrate. Molecular weight of BJC1 was estimated at 29,000 by gel filtration. Neither glycoprotein reacted with rabbit antiserum to normal human serum.

Antiserum to BJC1 was made in the rabbit. Immunoelectrophoresis with this antiserum showed a faint precipitin line, corresponding in mobility to BJC1, in normal human plasma, and a stronger line in most leukemic plasmas. By immunodiffusion, BJC1 was not detectable in normal human urine, but a positive reaction occurred in the following conditions: leukemia, 64-72%; other types of disseminated neoplastic disease, 36-78%; regional ileitis, 45%; ulcerative colitis, 38%; tuberculosis, 33%; during the 1st wk after major surgery, 33%.

BJC2 was found in the urine by immunoelectrophoresis in 10% of patients with neoplastic disease and was not observed in urine of other patients or in human plasma.

Amino acid composition, carbohydrate content, and antigenic specificity indicate BJC1 is a previously unrecognized member of the system of normal human plasma glycoproteins. Like certain other glycoproteins, its plasma concentration frequently increases in patients with neoplastic disease, chronic inflammatory disease, or tuberculosis and after surgery. Because molecular weight is 29,000, increased plasma concentration readily causes its appearance in the urine.

Full text

PDF
868

Images in this article

870Image
on p.870
871Image
on p.871
872Image
on p.872

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. DAVIS B. J. DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS. Ann N Y Acad Sci. 1964 Dec 28;121:404–427. doi: 10.1111/j.1749-6632.1964.tb14213.x. [DOI] [PubMed] [Google Scholar]
  2. GOA J. On protein-bound carbohydrates in human serum; a study on hexosamine and hexose content of electrophoretically separated fractions of normal and pathological sera. Scand J Clin Lab Invest. 1955;7 (Suppl 22):1–55. [PubMed] [Google Scholar]
  3. Krupey J., Gold P., Freedman S. O. Physicochemical studies of the carcinoembryonic antigens of the human digestive system. J Exp Med. 1968 Sep 1;128(3):387–398. doi: 10.1084/jem.128.3.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. MACBETH R. A., BEKESI J. G. THE EFFECT OF TRANSPLANTABLE TUMORS ON THE SEROMUCOID FRACTION OF RAT SERUM. Cancer Res. 1964 Dec;24:2044–2051. [PubMed] [Google Scholar]
  5. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  6. Old L. J., Boyse E. A. Current enigmas in cancer research. Harvey Lect. 1973;67:273–315. [PubMed] [Google Scholar]
  7. Owen J. A. Effect of injury on plasma proteins. Adv Clin Chem. 1967;9:1–41. doi: 10.1016/s0065-2423(08)60284-x. [DOI] [PubMed] [Google Scholar]
  8. Rudman D., Del Rio A. E., Garcia L. A., Barnett J., Bixler T., Hollins B. Lipolytic substances in bovine thyroid, parotid and pineal glands. Endocrinology. 1970 Jul;87(1):27–37. doi: 10.1210/endo-87-1-27. [DOI] [PubMed] [Google Scholar]
  9. Rudman D., Del Rio A. E., Hollins B. M., Houser D. H., Keeling M. E., Sutin J., Scott J. W., Sears R. A., Rosenberg M. Z. Melanotropic-lipolytic peptides in various regions of bovine, simian and human brains and in simian and human cerebrospinal fluids. Endocrinology. 1973 Feb;92(2):372–379. doi: 10.1210/endo-92-2-372. [DOI] [PubMed] [Google Scholar]
  10. Rudman D., Del Rio A., Akgun S., Frumin E. Novel proteins and peptides in the urine of patients with advanced neoplastic disease. Am J Med. 1969 Feb;46(2):174–187. doi: 10.1016/0002-9343(69)90002-3. [DOI] [PubMed] [Google Scholar]
  11. Rudman D., Treadwell P. E., Vogler W. R., Howard C. H., Hollins B. An abnormal orosomucoid in the plasma of patients with neoplastic disease. Cancer Res. 1972 Sep;32(9):1951–1959. [PubMed] [Google Scholar]
  12. Springer G. F., Nagai Y., Tegtmeyer H. Isolation and properties of human blood-group NN and meconium-Vg antigens. Biochemistry. 1966 Oct;5(10):3254–3272. doi: 10.1021/bi00874a028. [DOI] [PubMed] [Google Scholar]
  13. WARREN L. The thiobarbituric acid assay of sialic acids. J Biol Chem. 1959 Aug;234(8):1971–1975. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES